NZ 1002

Drug Profile

NZ 1002

Latest Information Update: 17 Oct 2007

Price : $50

At a glance

  • Originator Novazyme Pharmaceuticals
  • Class
  • Mechanism of Action Iduronidase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Mucopolysaccharidosis I

Most Recent Events

  • 04 Feb 2003 No development reported - Preclinical for Mucopolysaccharidosis type I in USA (unspecified route)
  • 20 Apr 2001 NZ 1002 has received orphan drug status for Mucopolysaccharidosis type I in USA
  • 22 Jan 2001 Preclinical development for Mucopolysaccharidosis type I in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top